Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,047.9
-15.2 (-0.50%)

 

  • STI Straits Times Index
    3,047.9
    -15.2 (-0.50%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,525.3
    -5.2 (-0.34%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    24,099.1
    -
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,591.1
    -22.9 (-0.63%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    29,665.4
    -174.3 (-0.58%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,104.7
    44.0 (0.73%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 801.5M
  • Value: 424.7M
  • Rise: 107
  • Fall: 130
  • Unch: 518

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Shen Yao0.004-0.001
Sembcorp Marine0.083-0.002
Aspen0.157+0.031
Asian Micro0.007-
Hatten Land0.068-0.001
YZJ Shipbldg SGD1.390-0.040
China Star Food0.029+0.005
VCPlus0.029+0.001
CapLand IntCom T2.080+0.030
Biolidics0.235-

World Indices

World Indices
Name Last Change
Nasdaq 14,746.4 +32.5
HSI 24,099.1
HSCEI 8,638.5
Jakarta 6,115.4 +54.6
Nikkei 225 29,665.4 -174.3
SSE Comp 3,591.6 -22.4
Shanghai A 3,764.2 -23.5
Shanghai B 274.2 +1.0
KOSPI 3,130.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

ABBVIE INC ABBVIE INC
Updated on 21 Sep 2021 (End of trading day)
Last (USD): 107.150 Change: +0.750 High: 107.410 Remarks: -
Change (%): +0.70 Low: 106.200
Open 106.250 Yesterday's Close 106.4
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 6,398,281 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a 2.57812 Trailing EPS (USD) e 3.72854 NAV (USD) b 7.1125
PE a 41.561 Trailing PE f 28.738 Price / NAV b 15.0650
Dividend (USD) d 4.834394 Cash In Hand (USD) g 4.8360 Issued & Paid-up Shares c 1,767,180,000
Dividend Yield (%) d 4.512 Price / Cash In Hand g 22.157 Treasury Shares h 34,015,942
Market Cap (M) 189,353.337 Enterprise Value (M) 262,916.337
Piotroski F Score 4 Exchange Code ABBV Par Value ( $ ) n.a.
52 Weeks Volatility (%) 22.15 Free Float (%) -
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 03 Aug 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 03 Aug 2021.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference ABBVIE INC NYSE 189,353.337 41.561 28.738 15.0650 4.512
Industry Pharmaceuticals: Major NYSE 115,322.831 32.887 27.604 5.4200 2.830
Local Peer JOHNSON & JOHNSON NYSE 433,121.934 29.436 24.378 6.2248 2.419
Local Peer PFIZER INC NYSE 246,245.825 25.608 18.615 3.5157 3.459
Local Peer ELI LILLY AND COMPANY NYSE 220,176.249 35.548 36.269 34.1656 1.286
Local Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 202,178.581 24.898 22.479 3.7411 2.321
Local Peer MERCK & CO INC NYSE 182,182.699 25.779 32.702 5.4719 3.444
Local Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 180,393.431 27.995 25.340 17.2541 1.322
Local Peer BRISTOL-MYERS SQUIBB CO NYSE 134,059.896 - - 3.6421 3.080
Local Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 98,320.200 13.337 16.577 4.6285 5.295
Local Peer TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS NYSE 54,492.862 15.370 13.494 1.1546 4.449
Local Peer BIOHAVEN PHARMACEUTICAL HLDG CO LTD NYSE 8,801.693 - - -19.3922 -
Local Peer ORGANON & CO NYSE 8,339.095 3.861 3.861 -4.3119 -
Local Peer EMERGENT BIOSOLUTIONS INC NYSE 2,920.781 9.573 9.762 1.8921 -
Other Local Peers ADC THERAPEUTICS SA (NYSE), ZYMEWORKS INC (NYSE), AMNEAL PHARMACEUTICALS INC (NYSE), LANNETT CO INC (NYSE)
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 183,200.114 57.322 48.581 11.6867 1.963
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 121,848.565 8.680 17.595 1.6248 2.773
Global Peer WUXI APPTEC HKEx 534,219.675 160.960 115.360 12.1010 0.195
Global Peer ROYALTY PHARMA PLC NASDAQ 22,240.710 22.810 22.893 3.8789 0.524
Global Peer REPLIGEN CORP NASDAQ 17,272.737 288.233 172.843 10.7748 -
Global Peer VIATRIS INC NASDAQ 16,059.371 - - 0.7573 -
Global Peer HANSOH PHARMA HKEx 118,091.659 40.909 38.217 5.2492 0.386
Global Peer INNOVENT BIO HKEx 99,765.504 - - 6.9723 -
Global Peer CANSINOBIO-B HKEx 94,007.719 - 119.364 11.1478 -
Global Peer CUREVAC NV NASDAQ 9,979.530 - - - -
Other Global Peers ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), SINOPHARM (HKEx), HUTCHMED (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), REMEGEN-B (HKEx), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), ALLAKOS INC (NASDAQ), SH PHARMA (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), JUNSHI BIO (HKEx), CMS (HKEx), HYGEIA HEALTH (HKEx), AKESO-B (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), BAIYUNSHAN PH (HKEx), INNOCARE-B (HKEx), TURNING POINT THERAPEUTICS INC (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), CARSGEN-B (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), CHINARES PHARMA (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), CHINAGRANDPHARM (HKEx), OPKO HEALTH INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), SIMCERE PHARMA (HKEx), ATEA PHARMACEUTICALS INC (NASDAQ), ERASCA INC (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), EVEREST MED-B (HKEx), TRAD CHI MED (HKEx), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), CSTONE PHARMA-B (HKEx), QUANTERIX CORPORATION (NASDAQ), HENLIUS (HKEx), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), SSY GROUP (HKEx), DICERNA PHARMACEUTICALS INC. (NASDAQ), OCUMENSION-B (HKEx), HEPALINK (HKEx), GENERATION BIO CO (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), KRONOS BIO INC (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), UNITED LAB (HKEx), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), ICOSAVAX INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), IMMUNOTECH-B (HKEx), CULLINAN ONCOLOGY INC (NASDAQ), TONGRENTANGCM (HKEx), REPARE THERAPEUTICS INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), Kimia Farma Tbk. (IDX), SCICLONE PHARMA (HKEx), GH RESEARCH PLC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), ANTENGENE-B (HKEx), KINNATE BIOPHARMA INC (NASDAQ), CKLIFE SCIENCES (HKEx), POINT BIOPHARMA GLOBAL INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), ANNEXON INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), SHINEWAY PHARM (HKEx), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), PETIQ INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), VERU INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), PHARVARIS NV (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), BEYONDSPRING INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), HUA MEDICINE-B (HKEx), TALARIS THERAPEUTICS INC (NASDAQ), ZHAOKE OPHTH-B (HKEx), CHINOOK THERAPEUTICS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), AC IMMUNE SA (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), Soho Global Health Tbk. (IDX), WEREWOLF THERAPEUTICS INC (NASDAQ), CLENE INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), EVOLUS INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), PROVENTION BIO INC (NASDAQ), IGBB (Bursa), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), 89BIO INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), ATHENEX INC (NASDAQ), RACE ONCOLOGY LTD (ASX), ESSA PHARMA INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), CYBIN INC (NYSE American), NEXIMMUNE INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), TOT BIOPHARM-B (HKEx), PYC THERAPEUTICS LIMITED (ASX), OYSTER POINT PHARMA INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), ANGION BIOMEDICA CORP (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), DAWNRAYS PHARMA (HKEx), DURECT CORP (NASDAQ), BSTEAD (Bursa), INOZYME PHARMA INC (NASDAQ), XOMA CORP (NASDAQ), OBSEVA SA (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), PHARMA (Bursa), VINCERX PHARMA INC (NASDAQ), HARROW HEALTH INC (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), ANNOVIS BIO INC (NYSE American), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), KALEIDO BIOSCIENCES INC (NASDAQ), MUSTANG BIO INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), IMMUNIC INC (NASDAQ), FUSEN PHARM (HKEx), GAMIDA CELL LTD (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), TRICIDA INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ALZAMEND NEURO INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), IP (SET), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), CH BIOTECH SER (HKEx), TYME TECHNOLOGIES INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), NOVAN INC (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), POLYPID LTD (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), ENTERA BIO LTD (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), GENPREX INC (NASDAQ), ZHONGZHIPHARM (HKEx), IX Biopharma (SGX), LANTERN PHARMA INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), EYENOVIA INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), IMARA INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), NOXOPHARM LTD (ASX), APREA THERAPEUTICS INC (NASDAQ), SANAI HEALTH GP (HKEx), ELEDON PHARMACEUTICALS INC (NASDAQ), CRESO PHARMA LTD (ASX), GALECTO INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), KOTRA (Bursa), TEMPEST THERAPEUTICS INC (NASDAQ), CHARMACY PHAR (HKEx), MEDIWOUND LTD (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), NEW RAY MEDIC (HKEx), OCUPHIRE PHARMA INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), GRAYBUG VISION INC (NASDAQ), PROPHASE LABS INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), Phapros Tbk. (IDX), PAK FAH YEOW (HKEx), NC HEALTHCARE (HKEx), NOVA (Bursa), Hyphens Pharma (SGX), BIOHLDG (Bursa), RENOVORX INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), ABVC BIOPHARMA INC (NASDAQ), INVION LTD (ASX), MANNATECH INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), MODERN CHI MED (HKEx), WAI YUEN TONG (HKEx), EXOPHARM LTD (ASX), NEP INTERLONG (HKEx), INHIBIKASE THERAPEUTICS INC (NASDAQ), UNIVERSE PHARMACEUTICALS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), ACURX PHARMACEUTICALS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), VALLON PHARMACEUTICALS INC (NASDAQ), SEQLL INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), PHARMAXIS (ASX), DERMATA THERAPEUTICS INC (NASDAQ), PURAPHARM (HKEx), CNS PHARMACEUTICALS INC (NASDAQ), PASITHEA THERAPEUTICS CORP (NASDAQ), MEDLAB CLINICAL LIMITED (ASX), ASSERTIO HOLDINGS INC (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), EXTRAWELL PHAR (HKEx), TELIGENT INC NEW (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), JCT (SET), PALLA PHARMA LTD (ASX), PAINREFORM LTD (NASDAQ), SUNZEN (Bursa), PANBELA THERAPEUTICS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), NLS PHARMACEUTICS LTD (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), IMMURON LIMITED (ASX), ACRUX (ASX), AVENUE THERAPEUTICS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), TALI DIGITAL LIMITED (ASX), ISLAND PHARMACEUTICALS LTD (ASX), PETROS PHARMACEUTICALS INC (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), SINOLIFE UTD (HKEx), SUDA PHARMACEUTICALS LTD (ASX), CHINA SXT PHARMACEUTICALS INC (NASDAQ), PASHUN INT'L (HKEx), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.620
-0.58 %
10 Days --3.210
-2.91 %
20 Days --13.250
-11.00 %
Medium Term Return 3 Months --6.850
-6.01 %
6 Months -+4.090
+3.97 %
1 Year 160.480+20.010
+207.13 %
Long Term Return 2 Years 349.170+35.060
+532.99 %
3 Years 353.340+12.970
+388.95 %
5 Years 359.100+42.930
+626.02 %
Annualised Return Annualised --
+48.66 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 79.110 - 121.530 Change From 1 Year Low +28.040 % Change From 1 Year Low (%) +35.44
Change From 1 Year High -14.380 % Change From 1 Year High (%) -11.83
2 Years Range 62.550 - 121.530 Change From 2 Years Low +44.600 % Change From 2 Years Low (%) +71.30
Change From 2 Years High -14.380 % Change From 2 Years High (%) -11.83
5 Years Range 55.062 - 125.860 Change From 5 Years Low +52.088 % Change From 5 Years Low (%) +94.60
Change From 5 Years High -18.710 % Change From 5 Years High (%) -14.87
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Historical Price Data

Date Open High Low Close Volume VWAP
21 Sep 2021 106.250 107.410 106.200 107.150 6,398,281 -
20 Sep 2021 106.100 107.490 105.560 106.400 7,099,775 -
17 Sep 2021 107.500 108.250 107.103 107.730 14,155,060 -
16 Sep 2021 108.240 108.750 106.530 108.080 5,820,122 -
15 Sep 2021 106.590 108.800 106.030 107.770 7,442,609 -
14 Sep 2021 107.990 108.070 106.250 106.480 6,098,913 -
13 Sep 2021 107.390 108.770 106.806 107.480 7,395,456 -
10 Sep 2021 107.480 108.320 106.360 106.680 7,615,291 -
09 Sep 2021 109.440 109.740 107.200 107.270 10,325,120 -
08 Sep 2021 108.060 110.900 107.720 110.360 10,814,290 -
07 Sep 2021 110.450 111.570 108.320 109.030 12,689,730 -
03 Sep 2021 111.180 112.070 111.020 111.620 5,363,765 -
02 Sep 2021 113.550 113.740 110.820 112.020 14,718,130 -
01 Sep 2021 121.000 121.530 106.100 112.270 50,869,680 -
31 Aug 2021 120.830 121.170 120.025 120.780 6,019,881 -
30 Aug 2021 119.840 120.900 119.540 120.570 3,259,519 -
27 Aug 2021 120.340 120.640 119.420 119.580 4,278,575 -
26 Aug 2021 120.860 121.250 120.150 120.400 5,032,239 -
25 Aug 2021 119.860 121.400 118.870 120.400 5,199,939 -
24 Aug 2021 119.720 119.720 118.420 119.680 3,830,217 -
23 Aug 2021 119.800 120.450 119.220 119.360 4,747,934 -
20 Aug 2021 118.100 119.470 117.650 118.820 4,107,426 -
Summary
Current 2 Weeks
(08 Sep 2021 to 21 Sep 2021)
108.060 110.900 105.560 107.150 83,164,917 -
Previous 2 Weeks
(24 Aug 2021 to 07 Sep 2021)
119.720 119.720 105.560 109.030 111,261,675 -
4 Weeks from
(27 Jul 2021 to 23 Aug 2021)
117.790 118.300 105.560 119.360 114,914,183 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.